Details

Autor(en) / Beteiligte

• Martin, Daniel F
• Maguire, Maureen G
• Ying, Gui-shuang
• Grunwald, Juan E
• Fine, Stuart L
• Jaffe, Glenn J

Titel

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

Ist Teil von

• The New England journal of medicine, 2011-05, Vol.364 (20), p.1897-1908

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2011

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• This comparison of ranibizumab and bevacizumab to treat neovascular age-related macular degeneration showed equivalent efficacy in maintaining visual acuity. Bevacizumab was associated with more serious adverse events (mainly hospitalizations). In 2005, clinical trials established the efficacy of ranibizumab 1 , 2 (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. While awaiting approval for ranibizumab from the Food and Drug Administration, ophthalmologists began treating neovascular AMD with off-label use of bevacizumab (Avastin, Genentech), since the drug had a target specificity similar to that of ranibizumab and was available at low cost. 3 , 4 Because the intraocular safety of bevacizumab and the duration of its therapeutic effect were unknown, the drug was usually administered only when there were signs of active . . .